


PHARMACEUTICAL 2022

Xilio Therapeutics Inc. Rank 152 of 466







PHARMACEUTICAL 2022

Xilio Therapeutics Inc. Rank 152 of 466



The relative strengths and weaknesses of Xilio Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xilio Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Xilio Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 194%, being 116% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	202,517
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,778
Liabilities, Non-Current	10,225
Other Assets	15,543
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	9,628
Other Net Income	-756
Other Revenues	0
Property and Equipment	0
Research and Development	51,188
Selling, General and Administrative Expense	23,856

Output Variable	Value in 1000 USD
Assets	218,060
Liabilities	32,631
Expenses	75,044
Revenues	0
Stockholders Equity	185,429
Net Income	-75,800
Comprehensive Net Income	-75,800
Economic Capital Ratio	194%

